Taro Pharmaceutical Industries (TARO)
Add to Watchlists Create an AlertTARO Key Stats
| Income Statement | |
| Revenue TTM | 650.96M |
| Revenue Quarterly YoY Growth | 25.38% |
| EPS Diluted TTM | 5.91 |
| EPS Diluted Quarterly YoY Growth | 40.76% |
| Net Income TTM | 264.29M |
| Profitability | |
| Gross Profit Margin Quarterly | 75.35% |
| Profit Margin Quarterly | 47.81% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 2.689B |
| Enterprise Value | 2.366B |
| PE Ratio TTM | 10.23 |
| PE 10 Pro | Go Pro |
| PEG Ratio | 0.2329 |
| Price / Book Value | 3.188 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.0336 |
| Free Cash Flow | 87.90M |
| Return on Equity | 38.11% |
TARO News
- Indian shares snap four-day losing streak; GDP, flows on watch 7:15 AM
- Sensex ends four-day losing streak; Tata Steel gains 6:12 AM
- Sun Pharma falls after unit's earnings disappoint 1:33 AM
- Taro Pharmaceutical Industries Ltd. (TARO) Reports Q1 EPS of $1.10 Street Insider May 23
- Taro Provides Results Year Ended March 31, 2013 Business Wire May 23
- Q4 2013 Taro Pharmaceutical Industries Ltd Earnings Release - After Market Close May 23
- BlueMountain Capital Is Bullish On These 5 Stocks Fool May 22
- Taro to Announce Results for Year Ended March 31, 2013 Business Wire May 16
- Antibodies Show Higher Probability of Success and a Higher Rate of M&A: Learn Wh... May 3
- My Thoughts On Taro Apr 14
TARO Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Taro Pharmaceutical Industries is up 46.40% over the last year vs S&P 500 Total Return up 27.81%, Perrigo Company up 17.85%, and Valeant Pharmaceuticals International up 81.01%.
TARO Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Cash Flow Statement View Statement
You may also be interested in these TARO related companies
Pro Ratings for TARO
Pro Report PDF for TARO
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download TARO Pro Report PDF
Pro Strategies Featuring TARO
Did Taro Pharmaceutical Industries make it into our Pro Portfolio Strategies?
TARO Profile
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Other TARO Resources
- Company Website
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| TARO | 60.45 | -2.77 | -4.38% | 2.689B |
